Transparency notification BlackRock, Inc.

Brussels (Belgium), 18 November 2024 – 20:00 (CET) – Regulated information 

1.  Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it received a transparency notification from BlackRock, Inc. (having its registered office at 50 Hudson Yards, New York, NY, 10001, U.S.A.), on 13 November 2024. 

BlackRock, Inc. notified that, following a disposal of UCB shares with voting rights by its affiliates, its shareholding in UCB SA decreased and crossed the 5% threshold downwards on 11 November 2024.

On 11 November 2024, BlackRock, Inc. (taking into account the holding of its affiliates) owned 9 644 241 UCB shares with voting rights and 114 302 assimilated financial instruments, representing together 5.02 % of the total number of shares issued by the company (194 505 658), versus 5.11% (9 858 386 UCB shares and 73 003 assimilated financial instruments) in the previous notification dated 7 November 2024.

2.  Content of the notification

• Reason for the notification: Acquisition or disposal of voting securities or voting rights.
• Notification by: A parent undertaking or a controlling person.
• Persons subject to the notification requirement: 

 

• Date on which the threshold is crossed: 11 November 2024. 
• Threshold crossed (in %): 5%.
• Denominator: 194 505 658.
• Notified details:

• Chain of controlled undertakings through which the holding is effectively held:

Please see the full chain of control in the ‘Chain of Control’ tab.

• Additional information: The disclosure obligation arose due to total holdings in voting rights for BlackRock, Inc. going below 5%. 

3.  Further information 

This press release and the detailed transparency notification are available on UCB SA/NV’s website via the following link.

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV’s website via the following link.

For further information, contact UCB: 

Investor Relations
Antje Witte 
T +32 2 559 94 14
antje.witte@ucb.com

Corporate Communications
Laurent Schots 
T+32 2 559 92 64
laurent.schots@ucb.com     

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news